---
schema_version: "secwatch.filing_event.v1"
accession: "0001434647-26-000029"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:35:44.543455+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Zevra Q1 2026 net revenue $36.2M (+78% YoY); net income $37.9M; cash $236.8M after debt repayment

## Summary
- MIPLYFFA net revenue $24.6M; total net revenue $36.2M vs $20.4M in Q1 2025.
- Completed $50M sale of SDX portfolio to Commave Therapeutics; prepaid $63.1M term loan, now debt-free.
- Net income of $37.9M ($0.60 diluted) includes $43.3M one-time gain; adjusted net income $11.5M ($0.18 diluted).
- Cash, equivalents and securities $236.8M as of March 31, 2026; no near-term capital market dependency.
- Enrolled 62 patients in Phase 3 DiSCOVER trial for Vascular Ehlers-Danlos Syndrome; FDA meeting expected H2 2026.

## SEC filing metadata
- accession: 0001434647-26-000029
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143464726000029/0001434647-26-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143464726000029/zvra-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001434647-26-000029
- JSON: https://secwatch.observer/filing/0001434647-26-000029.json
- Plain text: https://secwatch.observer/filing/0001434647-26-000029.txt

## Source-grounded claims
- claim_id: b3e99bb7fccac32485eee093b96af36d78e1cf4c
  claim: ZEVRA THERAPEUTICS, INC. reported the first quarter ended March 31, 2026 results: revenue $36.2 million, net income $37.9 million, EPS $0.62 per basic and $0.60 diluted share.
  evidence_excerpt: set forth by specific reference in any such filing. --- EX-99.1 (EX-99.1) --- Zevra Reports First Quarter 2026 Financial Results and Corporate Update Q1 2026 net revenue of $36.2 million, a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position of $236.8 million Company to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143464726000029/0001434647-26-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.